

**Novacyt S.A.**  
**("Novacyt", the "Company" or the "Group")**

## **DHSC dispute update**

**Paris, France and Camberley, UK – 26 April 2022** – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care ("DHSC").

On 9 April 2021, Novacyt announced it was in dispute with the DHSC regarding its second supply contract, announced on 29 September 2020. On 25 April 2022, the Company was notified that the DHSC has now issued a claim against Primerdesign Ltd and Novacyt S.A. for £134.6m relating to this contract. The claim amount is broadly in line with the disputed Q4 2020 revenue, as previously announced by the Company.

The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including in relation to recovering outstanding sums due from the DHSC.

The Company is unable to provide further comment at this time due to the ongoing nature of this claim but will provide further updates as appropriate.

*The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.*

### **Contacts**

#### **Novacyt SA**

David Allmond, Chief Executive Officer  
James McCarthy, Chief Financial Officer  
+44 (0)1276 600081

#### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)  
+44 (0)20 3470 0470

#### **Numis Securities Limited (Joint Broker)**

Freddie Barnfield / James Black / Duncan Monteith  
+44 (0)20 7260 1000

#### **Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit  
+33 (1) 42 22 10 10

[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

**FTI Consulting (International)**

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [Alex.Shaw@fticonsulting.com](mailto:Alex.Shaw@fticonsulting.com) /

[Novacyt.group@fticonsulting.com](mailto:Novacyt.group@fticonsulting.com)

**FTI Consulting (France)**

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

**About Novacyt Group**

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)